Peripheral neuropathy Board decisions

The Board denied service connection for bilateral hearing loss, diabetic neuropathy of the bilateral upper and lower extremities, a higher rating for prostate cancer, a higher rating for PTSD, and a compensable rating for keloids. The TDIU and DEA benefits claims were remanded.

The Board granted service connection for voiding dysfunction, secondary to diabetes mellitus, and increased the ratings for certain peripheral neuropathies.

The claims for service connection for diabetes mellitus and bilateral lower extremity peripheral neuropathy are remanded due to the need for additional evidence regarding herbicide exposure.

The May 2025 motion to revise the March 2019 Board decision on the basis of clear and unmistakable error (CUE) was dismissed.

The Board granted an effective date of May 20, 2022 for the grant of a 30 percent disability rating for diabetic peripheral neuropathy in both lower extremities and granted TDIU from December 13, 2016 to April 6, 2023.

The Veteran withdrew the appeal for earlier effective dates of service connection for various conditions, including PTSD, tension headaches, plantar fasciitis right foot, brachial plexus neuropathy left hand, and brachial plexus neuropathy right hand.

The Board denied service connection for diabetes mellitus, type II, right and left lower extremity diabetic neuropathy, degenerative disc disease with osteoporosis ('back disability'), and remanded the claim of service connection for nasopharyngeal cancer as due to exposure toxins for the period prior to August 10, 2022.

The Board denied service connection for various conditions and an earlier effective date, as well as a higher rating for hearing loss.

The Board remands the claims for service connection for a back disorder and related conditions due to insufficient evidence regarding the Veteran's duty status in May 2006 and the etiology of his claimed back disorder.

The appeal was dismissed for the proposed rating reduction of bilateral hearing loss, and various claims for service connection were denied.

The Board of Veterans' Appeals remands the claims for service connection for various conditions, including coronary artery disease, Parkinson's disease, hypertension, diabetes mellitus type II, and others, due to pre-decisional duty to assist errors.

The Board granted initial disability ratings for diabetic peripheral neuropathy of the right and left upper extremities, right and left lower extremities involving femoral and sciatic nerves, and a 70 percent rating for service-connected other specified depressive disorder with anxious distress (moderate), as well as a compensable rating for hypertension.

The Board remands the claims for service connection for right and left upper extremity neuropathy, to include trigger fingers, as further development is needed.

The Board denied service connection for tinnitus, left lower extremity radiculopathy/peripheral neuropathy, and a left knee meniscal tear. However, it granted service connection for right lower extremity sciatica.

The Board denied service connection for multiple conditions, including sinusitis, vertigo, and various musculoskeletal disorders, as the evidence did not support a finding of current disability or nexus to active duty.

The Board granted an earlier effective date of September 21, 2017, for the grant of service connection for left lower extremity diabetic peripheral neuropathy associated with diabetes mellitus type II and denied higher ratings for both left and right lower extremity diabetic peripheral neuropathy.

The Board denied the veteran's claims for increased ratings for various conditions, including impotence, headaches, cervical spine degenerative joint disease, and peripheral neuropathy of both upper and lower extremities.

The Board remands the issues of entitlement to higher initial and on-going evaluations for service-connected peripheral neuropathy in both lower extremities due to inadequate VA examination reports.

The Board granted service connection for diabetes mellitus, left lower extremity diabetic peripheral neuropathy, right lower extremity diabetic peripheral neuropathy, and erectile dysfunction. The CAD rating was increased to 60 percent effective February 23, 2021.

The issues of entitlement to increased ratings for bilateral lower extremity peripheral neuropathy were dismissed as moot because the Board had already adjudicated them on the merits.